Fig. 1 · Structure

Documents & Downloads

Vinpocetine

Cat. No. A11602 CAS 42971-09-5

PDE1 inhibitor

Vinpocetine is a Ca2+-calmodulin-dependent phosphodiesterase I (PDE1) inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
IKK IC50 17.17 μM

In Vitro Studies

Vinpocetine-treated 3T3-L1 adipocytes had 40% less lipid accumulation than dimethyl sulfoxide-treated control adipocytes. In PMA-induced macrophages subsequently incubated with ox-LDL, Vinpocetine pretreatment alone repressed Akt phosphorylation by 1.5-fold compared with ox-LDL alone. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Vinpocetine reduces lipid accumulation in adipocytes

Cell-based study · 3T3-L1 cells [1]

In 3T3-L1 cells, Vinpocetine treatment at 50 μg/ml and 100 μg/ml was evaluated using spectrophotometry. Vinpocetine-treated adipocytes had 40% less lipid accumulation than dimethyl sulfoxide-treated control adipocytes.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Lipid accumulation in 3T3-L1 cells was measured using spectrophotometrylipid accumulation 50 and 100 μg/ml; at 2 days after MDI treatment; 6 days after MDI treatment: 40% less lipid accumulation[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μg/ml and 100 μg/ml
Exposure duration
at 2 days after MDI treatment; 6 days after MDI treatment
Vehicle
dimethyl sulfoxide
Co-treatment
Other interventions in this design: insulin 1 μg/ml; isobutylmethylxanthine 520 μM; dexamethasone 1 μM. Compound effect isolated by the comparison: dimethyl sulfoxide-treated control adipocytes.
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Vinpocetine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Cell culture (S6, S7); Materials and methods > ORO staining (S22); Results > Vinpocetine inhibits the differentiation of 3T3-L1 cells and the expression of adipogenesis-associated factors (S41, S42, S50, S54, S55)

Lipid accumulation in 3T3-L1 cells was measured using spectrophotometry: Lipid accumulation in 3T3-L1 cells was measured using spectrophotometry; comparator: dimethyl sulfoxide-treated control adipocytes — Results > Vinpocetine inhibits the differentiation of 3T3-L1 cells and the expression of adipogenesis-associated factors (S41, S42, S50, S54, S55)

Vinpocetine represses ox-LDL-induced Akt phosphorylation in macrophages

Cell-based study · PMA-induced macrophages [2]

PMA-induced macrophages were pretreated with Vinpocetine at 30 μM before incubation with ox-LDL. Vinpocetine alone repressed Akt phosphorylation by 1.5-fold compared with ox-LDL alone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
ox-LDL-induced phosphorylation of AktAkt phosphorylation vinpocetine (30 μM), alone: repressed Akt phosphorylation by 1.5-fold[2]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM
Exposure duration
After pretreatment of vinpocetine for 1 hour, PMA-induced macrophages were then incubated with ox-LDL (20 μg/ml) for 12 hours
Method
pretreatment of vinpocetine
Co-treatment
Other interventions in this design: PMA 100 nM; ox-LDL 20 μg/ml. Compound effect isolated by the comparison: vs. ox-LDL alone.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Vinpocetine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > 2: Materials (S3); Materials and Methods > 4: In vitro experiments > Preparation of ox-LDL, cell culture and transfection (S32, S33); Materials and Methods > 4: In vitro experiments > Analysis of monocyte-endothelial cell adhesion (S38); Results > Vinpocetine inhibits ox-LDL-induced NF-κB activation through suppression of Akt, IKKα/β and IκB phosphorylation (S104); Figure 5 legend (S150, S154)

ox-LDL-induced phosphorylation of Akt: ox-LDL-induced phosphorylation of Akt; comparator: ox-LDL alone — Results > Vinpocetine inhibits ox-LDL-induced NF-κB activation through suppression of Akt, IKKα/β and IκB phosphorylation (S104); Figure 5 legend (S150)

In Vivo Studies

In apoE-/- mice receiving a high cholesterol diet, daily intraperitoneal Vinpocetine significantly decreased longitudinal lesion development compared with saline treatment. In ferrets, mean differential map contrast values for cardinal and oblique orientations in Ethanol+Vinpocetine animals were similar to those in Saline animals and higher than those in Ethanol animals. [2,3]

Vinpocetine decreases lesion development in apoE-/- mice

Animal study · Six-week-old male apoE-/- mice on the C57BL/6 background strain (n = 22) [2]

In apoE-/- mice receiving a high cholesterol diet, Vinpocetine was injected intraperitoneally every day. Treatment significantly decreased longitudinal lesion development compared with saline-treated apoE-/- mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
percentage lesion arealesion area 5mg/kg every day for 12 weeks from 6 weeks of age: lesion area 19.63 ± 2.73% vs. 31.78 ± 1.92%[2]

Conditions shared by the study groups

Route
intraperitoneally injected
Treatment course
every day for 12 weeks from 6 weeks of age
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vinpocetine 5mg/kgsaline-treated apoE-/- micevinpocetine treatment significantly decreased longitudinal lesion development in apoE-/- mice compared with saline-treated apoE-/- mice (lesion area 19.63 ± 2.73% vs. 31.78 ± 1.92%; P=0.0066, n = 5)[2]
Vinpocetine 5mg/kg
Model: Six-week-old male apoE-/- mice on the C57BL/6 background strain (n = 22)
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Vinpocetine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > 3: In vivo experiments > Animals (S11, S12); Results > Vinpocetine suppresses atherosclerotic development in apoE-/- mice (S81, S82)

percentage lesion area: percentage lesion area; comparator: saline-treated apoE-/- mice — Materials and Methods > 3: In vivo experiments > Animals (S12); Results > Vinpocetine suppresses atherosclerotic development in apoE-/- mice (S81, S82)

Vinpocetine 5mg/kg · Materials and Methods > 3: In vivo experiments > Animals (S12); Results > Vinpocetine suppresses atherosclerotic development in apoE-/- mice (S82)

Differential map contrast in ethanol-exposed ferrets receiving Vinpocetine

Animal study · Ethanol+Vinpocetine (cardinal: 21,083.99±2262.95; oblique: 16,650.97±1890.02; n = 8 ferrets) treated animals [3]

Six days after the end of the alcohol treatment, animals received vinpocetine (40 mg/kg oral or 20 mg/kg i.p., see methods) or vehicle every day between P36 to P41. The results were similar between these groups and the animals were pooled together. Mean contrast values (±SEM) for cardinal and oblique orientations in Ethanol+Vinpocetine treated animals were similar to Saline treated animals, and higher than in Ethanol treated animals.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
contrast of differential mapscontrast of differential maps 40 mg/kg oral or 20 mg/kg i.p., every day between P36 to P41; animals were pooled together: cardinal: 21,083.99±2262.95; oblique: 16,650.97±1890.02[3]

Conditions shared by the study groups

Route
oral or 20 mg/kg i.p.
Treatment course
every day between P36 to P41
Vehicle
Nutrical©; DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vinpocetine 40 mg/kg oral or 20 mg/kg i.p.alcohol treated animals received Nutrical© (oral, n = 7) or DMSO solution (i.p., n = 2)Mean contrast values (±SEM) for cardinal and oblique orientations in Ethanol+Vinpocetine (cardinal: 21,083.99±2262.95; oblique: 16,650.97±1890.02; n = 8 ferrets) treated animals were similar to Saline (cardinal: 19,656.18±1246.99; oblique: 18,472.25±1586.58; n = 11) treated animals, and higher than in Ethanol (cardinal: 12,351.60±2193.15; oblique: 9,186.30±1887.37; n = 9) treated animals[3]
Vinpocetine 40 mg/kg oral or 20 mg/kg i.p.
Model: Ethanol+Vinpocetine (cardinal: 21,083.99±2262.95; oblique: 16,650.97±1890.02; n = 8 ferrets) treated animals
Methods and source locations

Compound reported in the paper: Vinpocetine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results (S1, S5); Results > Restoration of orientation selectivity maps (S14, S16); Methods > Treatments (S68, S69, S70); Methods > Optical imaging of intrinsic signals (S77, S80, S86, S87, S91, S92, S95); Figure 1 legend (S169)

contrast of differential maps: contrast of differential maps; comparator: alcohol treated animals received Nutrical© (oral, n = 7) or DMSO solution (i.p., n = 2) — Results (S5); Results > Restoration of orientation selectivity maps (S14, S16); Methods > Treatments (S69)

Vinpocetine 40 mg/kg oral or 20 mg/kg i.p. · Results (S5); Results > Restoration of orientation selectivity maps (S16)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 42971-09-5
Applications PDE1 inhibitor
Formula C22H26N2O2
Molecular Weight 350.45
SMILES
CC[C@@]12CCCN3[C@@H]1C4=C(CC3)C5=CC=CC=C5N4C(=C2)C(=O)OCC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 3 mg/mL (8.56 mM)
Water Insoluble
Ethanol <1 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Kim NJ, Baek JH, Lee J, et al. A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling. Exp Mol Med (2019). PMID: 30635550 DOI: 10.1038/s12276-018-0198-7 Source material
  2. [2] Zhuang J, Peng W, Li H, et al. Inhibitory effects of vinpocetine on the progression of atherosclerosis are mediated by Akt/NF-κB dependent mechanisms in apoE-/- mice. PLoS One (2013). PMID: 24349299 DOI: 10.1371/journal.pone.0082509 Source material
  3. [3] Krahe TE, Wang W, Medina AE. Phosphodiesterase inhibition increases CREB phosphorylation and restores orientation selectivity in a model of fetal alcohol spectrum disorders. PLoS One (2009). PMID: 19680548 DOI: 10.1371/journal.pone.0006643 Source material

Added to your cart

View Cart Checkout
Loading...